NasdaqGS:LEGNBiotechs
Assessing Legend Biotech (LEGN) Valuation After FDA Draft Guidance Favors CARTITUDE 6 Trial Design
Recent FDA draft guidance supporting Minimal Residual Disease negativity and complete response rate as expedited approval endpoints in multiple myeloma has put fresh attention on Legend Biotech (LEGN) and its CARTITUDE-6 trial design.
See our latest analysis for Legend Biotech.
Despite the positive regulatory backdrop and the recent appointment of Gareth Kung to the board and as Audit Committee chair, Legend Biotech’s shares have been under pressure, with a 30 day share price return of a...